Immatics is a clinical-stage biopharmaceutical company at the forefront of the discovery and development of T cell–based immunotherapies to treat cancer. Its mission is to open new therapeutic ...

BofA lowered the firm’s price target on Immatics (IMTX) to $13 from $15 and keeps a Buy rating on the shares. While political and rate ...

Immatics (IMTX) has released an update. Don't Miss our Black Friday Offers: Immatics reported a significant increase in collaboration revenue for the nine months ending September 30, 2024 ...